Product Pipeline
BIOxHEAL
351 Biologic Advanced Wound Care Product
Our 351 Biologic Advanced Wound Care Product represents a next-generation approach to tissue repair and regenerative healing. Pending Phase 3 clinical trial, this biologic therapy is being developed to address complex, chronic wounds through active biologic mechanisms rather than passive coverage.
Clinical Indications
Our investigational therapy targets major chronic wound types, including:
- Diabetic Foot Ulcers (DFU)
- Venous Leg Ulcers (VLU)
- Pressure Ulcers
These indications represent critical unmet needs in wound care where current therapies often fail to achieve durable closure or tissue regeneration.
Commitment to Innovation & Patient Outcomes
Our mission is to redefine wound care through biologic innovation—advancing from passive wound management to active biologic healing. With Phase 3 data forthcoming, this product represents a major step toward improving outcomes for patients suffering from chronic, non-healing wounds.
Regulatory & Development Pathway
Developed under the BLA (Biologics License Application) pathway, ensuring the highest FDA standards for safety, efficacy, and manufacturing consistency.
Designed as a true wound-healing biologic, not merely a “wound cover.” The product works at the cellular and molecular levels to stimulate tissue regeneration, improve vascularization, and enhance the body’s natural healing response.
BIOxHEAL represents the next-generation approach to tissue repair and regenerative healing, working at the cellular and molecular levels to stimulate tissue regeneration, improve vascularization, and enhance the body’s natural healing response.